Brett E Fortune MD

Chief Medical Officer, Miami Transplant Institute, @JacksonHealth, portal HTN, IR/hep, disparities, vascular liver disease/ opinions mine alone

[Elliot Tapper @ebtapper]

Follow @JenLaiLiverDoc

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

Donor BMI rises, liver biopsy use in LDLT is plummeting.

🇺🇸 In 7,942 LDLTs (2000–2024), donor BMI rose 24.6→27.6, while biopsy use fell ~50%→6%. Higher BMI was not linked to worse recipient outcomes.

Time to standardize steatosis assessment?

https://t.co/fwBrrSeXMD

#LiverX

[Hepatology Communications @HepCommJournal]

📑 Better pathways ➡️ better detection 🔎of advanced #MASLD‼️

⭐️A 2-step FIB4/MAF4/NFS ➡️ VCTE pathway ⬆️ correct hepatology referral rates❕
#OpenAccess #LiverX

https://t.co/Yo8JfnVduZ

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

Can a deceased donor–derived predictor guide decisions in living donor LT for ACLF? 🧐

In 178 LDLT recipients, SALT-M showed limited discrimination (AUROC 0.56).

Model failure or simply a different patient population? Use with caution ☝️

🔗 https://t.co/qLLgKSZ8qu

[Brett E Fortune MD @BrettEFortuneMD]

@adyeoman @basl_events @LiverUK_charity Congratulations 🎉!!! Well deserved!!!

[JHEP Reports @JHEP_Reports]

🟣 Beyond the class effect: Rethinking anticoagulation in #LiverdBeyond
🔓#OpenAccess at👉https://t.co/I6Qo9Vg7ml

#Liverdisease #LiverTwitter #LiverX

[JHEP Reports @JHEP_Reports]

🟣#Livertransplantation at the extreme: Analysis of outcomes and predictors of futility in patients with acute-on-chronic liver failure grade 3 on maximal life support
🔓#OpenAccess at👉https://t.co/GIBAb0w0Xa

#Livertransplantation #ACLF #LiverTwitter #LiverHealth #LiverX

[Sayed S Rahman @SayedSRahman1]

Thrombosis and anticoagulation in patients with Cirrhosis.
An overview

https://t.co/lHlVM2jnWX

[Anand V Kulkarni @AnandVKulkarni2]

Large multicenter study from India and Singapore.
Highlights:
TIPS is excellent for AVB (>90% control); decent for Ascites (50% control);
For HRS-AKI: survival 52% compared to 73% in no HRS.
First study on ACLF type A (APASL)- TFS 33%
FIPS and MELD are valid in Asian cohorts
@DrMarkMuthiah @DrHuangDQ @RoyAHep @karanbjmc93 @giri_gutnliver @docMPK @BavenoCoop @JimmyLaiCT @Sanchit30497977 @BrettEFortuneMD @ebtapper @JustSagnik @drshalimar @MaiwallRakhi @JasmohanBajaj #liverx #portalhypertension https://t.co/HpsVvYtpqc

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

Why does portal vein thrombosis matter in hospitalized patients with cirrhosis?

In the global CLEARED cohort investigating 7,721 patients across 37 countries, PVT affected 1 in 10 and was linked to more AKI, severe HE, and higher 30-day mortality.
https://t.co/ABWDiSjrkl
#LiverX

[Elliot Tapper @ebtapper]

Dreams can come true.
>10 years of research, friendship, and team building with patients and caregivers brought us to these beautiful results.

Together we (@serperm) prevented falls in patients with cirrhosis.

https://t.co/SBgFiF0Maf

[Jen Lai @JenLaiLiverDoc]

1/ It's #MalnutritionAwarenessWeek. Malnutrition is common in cirrhosis, and we've known it for decades. What we haven't done is build it into routine care the way we did carvedilol and pHTN. We need to routinely screen for it and proactively manage it when present.

[Brett E Fortune MD @BrettEFortuneMD]

@adyeoman Excellent 😎!!! Let me know if going to any upcoming conferences!

[Brett E Fortune MD @BrettEFortuneMD]

Seeking an energetic and motivated transplant hepatologist (board eligible or certified gastroenterology and transplant hepatology) who wants to join an exciting opportunity to be part of the new vision for advanced liver care and liver transplant at Miami Transplant Institute. Any rank and experience accepted. Please apply using the link below. https://t.co/hSULv1bCsk

[Brett E Fortune MD @BrettEFortuneMD]

🚨 job alert!! 🚨
@JacksonHealth @univmiami @AASLDtweets @AASLDFoundation @AST_info @LiverFellow @_ILTS_

[Brett E Fortune MD @BrettEFortuneMD]

🚨 job alert!! 🚨
@JacksonHealth @univmiami @AASLDtweets @AASLDFoundation @AST_info @LiverFellow @_ILTS_

[Brett E Fortune MD @BrettEFortuneMD]

Seeking an energetic and motivated transplant hepatologist (board eligible or certified gastroenterology and transplant hepatology) who wants to join an exciting opportunity to be part of the new vision for advanced liver care and liver transplant at Miami Transplant Institute. Any rank and experience accepted. Please apply using the link below. https://t.co/hSULv1bCsk

[Brett E Fortune MD @BrettEFortuneMD]

Seeking an energetic and motivated transplant hepatologist (board eligible or certified gastroenterology and transplant hepatology) who wants to join an exciting opportunity to be part of the new vision for advanced liver care and liver transplant at Miami Transplant Institute. Any rank and experience accepted. Please apply using the link below. https://t.co/hSULv1bCsk

[Brett E Fortune MD @BrettEFortuneMD]

Strong to you and your team @ebtapper !!!

[Elliot Tapper @ebtapper]

The updated impact factor for @HepCommJournal is now 6.2, up 35% from the prior year

On the clinical side we have had the same crew of AEs from the start. Neehar, @IanARowe, @DoctorSharad, @BloomPringle, and @DrLChina

This year Lok went to hepatology and we welcomed @ponnivp

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

6.9% of LT candidates were delisted after clinical improvement. But when is “better” good enough to leave the waitlist?

Khan & Aby: recovery varies by etiology and timing, and MELD improvement may not equal durable recompensation.

Better markers needed.

https://t.co/sCLiNkaAK8